List view / Grid view
18 November 2014 | By Public Health England
Four in ten people take antibiotics for a cough or runny nose despite both conditions normally clearing up without treatment, according to new research out by Public Health England (PHE) for European Antibiotic Awareness Day (EAAD)...
People aged 65 and older, who were being treated for chronic obstructive pulmonary disease (COPD) in the hospital and received nutrition treatment (oral nutrition supplements) had reduced lengths of stay, hospital costs and chances of returning to the hospital within 30-days, according to a study published in CHEST...
18 November 2014 | By LNC
The results of the Obeminale program demonstrate the safety and efficacy of Stablor, with an average of 18% fat loss and 9% weight loss in overweight and obese people...
18 November 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced results of several new sub-analyses of the Phase IIIb AVERT (Assessing Very Early Rheumatoid arthritis Treatment) trial that investigated the use of Orencia plus methotrexate (MTX) in biologic and MTX-naïve citrullinated protein (CCP)-positive early moderate to severe rheumatoid arthritis (RA) patients...
18 November 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer Inc. announced results from the first part of the Phase 3 ANNEXA™-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors – Apixaban) studies...
17 November 2014 | By Probiodrug
Probiodrug AG, a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s Disease, announces that Prof. Hans-Ulrich Demuth, co- founder and consultant of Probiodrug, will be reviewing the target validation and summarize data on its lead product candidate PQ912 at two international conferences...
17 November 2014 | By Moberg Pharma
Moberg Pharma AB announces that George E. Aitken-Davies has resigned from the Board of Directors of Moberg Pharma in conjunction with the final earn-out payment related to the acquisition of Alterna LLC in 2012...
17 November 2014 | By Moberg Pharma
"We made excellent progress in the third quarter, growing at 35% with improved profitability and reporting strong phase II data for MOB-015 in nail fungus..."
17 November 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced results from CheckMate -066, a Phase 3 randomized double blind study, comparing Opdivo, an investigational PD-1 immune checkpoint inhibitor, to the chemotherapy dacarbazine (DTIC) in patients with treatment naïve BRAF wild-type advanced melanoma (n=418)...
17 November 2014 | By The International Longevity Centre
Councils must ensure that spending cuts and short term targets do not undermine long-term investment in the prevention of ill health in old age...
17 November 2014 | By Medidata
Joint initiative evaluates impact of mHealth and cloud-based technologies on patient engagement, data quality and operational efficiencies in clinical trials...
17 November 2014 | By Roche
Avastin plus chemotherapy reduced the risk of the disease worsening by 62 percent compared to chemotherapy alone in a Phase III study...
14 November 2014 | By MedImmune and Advaxis
Dose confirmation safety study of ADXS-HPV and MEDI4736 combination therapy to initiate in early 2015...
14 November 2014 | By GlaxoSmithKline
GSK launched the first call for proposals for its Africa NCD Open Lab, to support much-needed scientific research into non-communicable diseases (NCDs) in Africa...
14 November 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced plans to construct a new state-of-the-art, large-scale biologics manufacturing facility in Cruiserath, County Dublin, Ireland, that will produce multiple therapies for the company’s growing biologics portfolio...
